Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs

PURPOSE: NSC 743400 is a novel synthetic indenoisoquinoline analog under development as an anticancer agent. It is a potent topoisomerase I inhibitor with potential therapeutic advantages over FDA-approved camptothecin derivatives. In preparation for clinical development of NSC 743400, we determined...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Muzzio, Miguel, Hu, Shu-Chieh, Holleran, Julianne L., Parise, Robert A., Eiseman, Julie L., Yellow-Duke, Archibong E., Covey, Joseph M., Glaze, Elizabeth R., Engelke, Kory, Egorin, Merrill J., McCormicka, David L., Beumer, Jan H.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4420695/
https://ncbi.nlm.nih.gov/pubmed/25776905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2722-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars